Darbepoetin alfa Amgen

Current Opinion in Investigational Drugs

Volumn 2, Issue 8, 2001, Pages 1097-1104

  Locatelli, F ^a   Del Vecchio, L ^a  

^a A MANZONI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DARBEPOIETIN ALFA; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANEMIA; BINDING AFFINITY; CANCER; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DIALYSIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG COST; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; HEADACHE; HUMAN; HYPERTENSION; INJECTION PAIN; KIDNEY DISEASE; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; VASCULAR DISEASE;

ANEMIA; ANIMALS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; ERYTHROPOIETIN; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034882601     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Amgen announces start of NESP clinical trials
2. Promising NESP phase III data presented at American Society of Nephrology meeting
3. Novel erythropoiesis stimulating protein (NESP) alleviates anemia associated with chronic inflammatory disease in a rodent model
4. Pretreatment with novel erythropoietin stimulating protein (NESP) prevents chemotherapy-induced anemia in mice
5. Amgen announces record financial results and regulatory submissions for both NESP and Kineret
6. Merrill Lynch: Global Healthcare Bulletin - Merrill Lynch's Global Pharmaceutical, Medical Technology & Products, and Biotechnology Conference, New York City
7. Drug development pipeline: NESP
8. Novel erythropoeitins stimulating protein (NESP) exhibits a prolonged serum half-life (t1/2) in oncology patients
9. Amgen announces 12% increase in second-quarter earnings per share, approval of NEUPOGEN - Syringe and European II-1ra regulatory filing
10. First efficacy data from cancer trials of Amgen's Aranesp presented at ESMO
11. Repeat/Aranesp and calcimimetics clinical data presented at American Society of Nephrology meeting
12. Major M&A may take place in Japan: Security analyst
13. Anemia of chronic disease (ACD) in rodent model is similar to human and can be alleviated by Aranesp
14. Rational design of novel erythropiesis stimulating protein (Aranesp): A super-desilylated molecule with increase biological activity
15. Open-label, phase I/II dose-escalation study of ARANESP in patients with chronic anemia of cancer
16. A randomized, blinded, placebo-controlled, phase II, dose-finding study of ARANESP in patients with lymphoproliferative malignancies
17. Randomized, double-blind, placebo controlled, phase I/II dose finding study of ARANESP administered once every three weeks in solid tumor patients
18. Product pipeline - Amgen marketed products and pipeline candidates - Product candidates in the pipeline
19. Amgen signs agreement with Genesis Pharma for distribution in Greece and Cyprus
20. Amgen Inc
21. Kirin aims at early launching of Espo successor
22. Amgen reports financial results and announces success of pivotal ARANESP oncology trial
23. Amgen victory in TKT litigation eases pressure to seek NESP reimbursement
24. Amgen signs agreement with MegaPharm for Aranesp distribution in Israel
25. CPMP recommends Amgen's Aranesp for European marketing approval
26. Kirin Brewery to survive by focusing on cancer, nephrology, allergy/immunology
27. Novel erythropoiesis stimulating protein. Antianemic. Cases A
28. Novel erythropoiesis-stimulating protein: An erythropoietin analogue with an extended half-life and less frequent dosing
29. Studies show new long-acting form of erythropoietin boosts blood hemoglobin levels in anemic cancer patients during chemotherapy: Investigational drug offers potential for more convenient, less frequent dosing than erythropoietin for patients undergoing chemotherapy
30. Randomized, active-controlled, phase 1/2, dose-escalation study of NESP administered weekly and every 2 weeks in patients with solid tumors
31. A randomized, blinded, placebocontrolled, phase II, dose-finding study of novel erythropoiesis stimulating protein (NESP) in patients with lymphoproliferative malignancies
32. Development and characterization of novel erythropoiesis stimulating protein (NESP)
33. Novel erythropoiesis stimulating protein (NESP) has longer serum half-life and greater in vivo biological activity than recombinant human erythropoietin (rHuEPO)
34. Novel erythropoiesis stimulating protein (NESP) for the treatment of renal anemia
35. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoietin alfa in dialysis patients
36. The in vivo metabolism of recombinant human erythropoietin in the rat
37. Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis
38. The pharmacokinetics of novel erythropoiesis stimulating protein (NESP) following chronic intravenous administration is time and dose linear
39. The pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in pediatric patients with chronic renal failure (CRF) or end-stage renal disease
40. Novel erythropoiesis stimulating protein
41. Novel erythropoiesis stimulating protein (NESP) maintains hemoglobin in ESRD patients when administered once weekly or once every other week
42. Erythropoiesis Stimulating Protein (NESP) safety maintains hemoglobin concentration levels in hemodialysis patients as effectively as rHuEPO when administered once weekly
43. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency
44. Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer
45. A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy
46. Novel erythropoiesis stimulating protein (NESP) corrects anemia in dialysis patients when administered at reduced dose frequency compared with recombinant-human erythropoietin (r-HuEPO)
47. Novel erythropoiesis stimulating protein (NESP) maintains hemoglobin (Hgb) in ESRD patients when administered once weekly or once every other week
48. European Commission approves Amgen's ARANESP for anaemia related to chronic kidney failure
49. Drug development pipeline: Aranesp